ABCELLERA BIOLOGICS INC (ABCL) Stock Analyst Ratings
USA - NASDAQ:ABCL - CA00288U1066 - Common Stock
4.69 USD
-0.18 (-3.7%)
4.73 USD
+0.04 (+0.85%)
ChartMill assigns a Buy % Consensus number of 83% to ABCL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.47. This target is 101.95% above the current price.
ABCL was analyzed by 14 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ABCL.
In the previous month the buy percentage consensus was at a similar level.
ABCL was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-08 | Stifel | Maintains | Buy -> Buy |
| 2025-07-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-05-16 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-16 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-03-03 | Benchmark | Reiterate | Hold -> Hold |
| 2025-02-28 | Stifel | Maintains | Buy -> Buy |
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-11-05 | Benchmark | Reiterate | Hold |
| 2024-11-05 | Stifel | Reiterate | Buy -> Buy |
| 2024-08-20 | Benchmark | Downgrade | Buy -> Hold |
| 2024-07-11 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-05-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-22 | Benchmark | Upgrade | Hold -> Buy |
| 2024-02-21 | Stifel | Maintains | Buy -> Buy |
| 2023-12-05 | Keybanc | Initiate | Overweight |
| 2023-08-31 | Benchmark | Maintains | Buy -> Buy |
| 2023-08-04 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-05-05 | Credit Suisse | Maintains | Outperform |
| 2023-02-28 | Cowen & Co. | Initiate | Outperform |
| 2023-02-22 | BMO Capital | Maintains | Outperform |
| 2023-02-22 | Credit Suisse | Reiterate | Outperform |
| 2023-01-06 | SVB Leerink | Maintains | Outperform |
| 2022-12-15 | Goldman Sachs | Initiate | Buy |
| 2022-11-16 | Truist Securities | Initiate | Buy |
| 2022-11-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-10 | Credit Suisse | Maintains | Outperform |
| 2022-07-26 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | Piper Sandler | Maintains | Overweight |
| 2022-02-25 | SVB Leerink | Maintains | Outperform |
ABCELLERA BIOLOGICS INC / ABCL FAQ
What is the average price target for ABCELLERA BIOLOGICS INC (ABCL) stock?
14 analysts have analysed ABCL and the average price target is 9.47 USD. This implies a price increase of 101.95% is expected in the next year compared to the current price of 4.69.
What is the consensus rating for ABCELLERA BIOLOGICS INC (ABCL) stock?
The consensus rating for ABCELLERA BIOLOGICS INC (ABCL) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ABCELLERA BIOLOGICS INC (ABCL) stock?
The number of analysts covering ABCELLERA BIOLOGICS INC (ABCL) is 14.